Table 2.
The mean volume (mm3) 1of tumor mass following immunization.
| Control group2 | pcDNA3.1-CS1 | pcDNA3.1-CS1/CRT | |
|---|---|---|---|
| D113 | 10.34 ± 4.87 | 10.77 ± 3.93 | 11.31 ± 5.62 |
| D13 | 43.43 ± 20.09 | 41.95 ± 16.48 | 43.07 ± 11.08 |
| D15 | 130.17 ± 44.57 | 108.61 ± 30.16 | 81.36 ± 35.36 |
| D17 | 251.30 ± 62.53 | 114.76 ± 26.39 | 100.85 ± 49.32 |
| D184 | 415.17 ± 104.57 | 138.59 ± 29.70 | 116.05 ± 47.66 |
| D20 | 751.30 ± 152.53 | 271.35 ± 65.11 | 129.17 ± 47.09 |
| D22 | 1251.30 ± 252.53 | 312.19 ± 62.03 | 242.75 ± 47.84 |
| D24 | 1496.70 ± 194.04 | 437.01 ± 92.89 | 260.95 ± 54.88 |
| D26 | 1707.86 ± 269.95 | 491.09 ± 78.02 | 324.96 ± 64.55 |
1Data are presented as the mean ± SD; n=6/group.
2BALB/c mice were vaccinated with the control plasmid, pcDNA3.1.
3There was no significantly different between the two experiment groups and the control group (mean ± SD. P > 0.05, respectively) in the size of tumor at the time of the first immunization.
4The group mean tumor volumes were significantly different between the two experiment groups and the control group (mean ± SD. P < 0.01, respectively), and there was also significant difference between the CS1 and CS1/CRT group (mean ± SD. P < 0.05), when the booster injection was administrated on D18 (seven days after the first injection).